Third Party Payer Guidelines 11.2019
တၢ်ဃုသ့ၣ်ညါတၢ်အစၢ
တၢ်ပာ်ဖျါ 1511 - 1520 လၢ 4179 အစၢတဖၣ်အကျါ
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
BCBSMN-Upcoming-Pharm-Policy-Notif-040121.pdf
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
Disclosure of Ownership and Management Information Form
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
QP16-21 Overpayment Refund/Recoupment Notification Process for Minnesota Health Care Programs
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲအမုၢ်နံၤမုၢ်သီ- လါဖ့ၤဘြူၤအါရံၤ 10, 2021
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
QP15-21 Provider Fee Schedule Request
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲအမုၢ်နံၤမုၢ်သီ- လါဖ့ၤဘြူၤအါရံၤ 10, 2021
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
QP14-21 MHCP Pharmacy Benefit Update – New Drug-Related Prior Authorization (PA) with Quantity Limit (QL) Criteria: Enspryng™(satralizumab-mwge) PAQL
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲအမုၢ်နံၤမုၢ်သီ- လါဖ့ၤဘြူၤအါရံၤ 10, 2021
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
QP13-21 Commercial and MHCP Pharmacy Benefit Exclusion for Cabenuva
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲအမုၢ်နံၤမုၢ်သီ- လါဖ့ၤဘြူၤအါရံၤ 10, 2021
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
QP9-21 New Request Form for Medical Policy Coverage Exception Requests for Commercial Members
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲအမုၢ်နံၤမုၢ်သီ- လါဖ့ၤဘြူၤအါရံၤ 10, 2021
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
QP11-21 Commercial Pharmacy Benefit Exclusion for Select Medications
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲအမုၢ်နံၤမုၢ်သီ- လါဖ့ၤဘြူၤအါရံၤ 10, 2021
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
QP10-21 Commercial Pharmacy Benefit Exclusion for Emtricitabine-Tenofovir Disoproxil Fumarate Tablet 100-150 mg, 133-200 mg, and 167-250 mg
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲအမုၢ်နံၤမုၢ်သီ- လါဖ့ၤဘြူၤအါရံၤ 10, 2021